Article
Bleomycin alters intratumoral immune response of EBV-associated gastric cancer by ENTPD8 and PCOLCE2
2023-05-24
Abstract excerpt
<title>Abstract</title><p>Background EBV-associated gastric cancer (EBVaGC) with high PD-L1 level, is most likely to be the next subgroup benefited from immunotherapy. However, complicated with histological and aetiological heterogeneity, tolerance persists which was usually alleviated by clinical adjuvant chemotherapy (bleomycin). Identifying biomarkers of intratumoral immune response was critical for further und...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- db13ad93-f26e-51d6-b562-65063d851c3f
- DOI
- 10.21203/rs.3.rs-2958586/v1
